Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks

2025-05-31
Stock prices can tumble for all sorts of reasons, but not every beaten-down stock deserves to be written off. Some are weighed down by weak fundamentals or lackluster performance, while others are simply caught in the broader market tide. When a company’s core business remains strong, a dip in its share price might just be a golden opportunity in disguise. Finding those diamonds in the rough is what separates the savvy investors from the rest. Hone this skill, and you’re well on your way to buil

1 Small-Cap Stock to Research Further and 2 to Brush Off

2025-05-30
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

American Airlines, Omnicell, Integra LifeSciences, Enovis, and Warby Parker Shares Are Soaring, What You Need To Know

2025-05-27
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand.

Exploring May 2025's Undervalued Small Caps With Insider Activity

2025-05-23
Over the last 7 days, the United States market has experienced a slight decline of 1.4%, yet it has shown resilience with an 11% rise over the past year, and earnings are anticipated to grow by 14% annually in the coming years. In this context, identifying stocks that exhibit strong insider activity can be crucial for investors seeking opportunities amidst current market conditions.

Why Omnicell (OMCL) Stock Is Trading Up Today

2025-05-22
Shares of healthcare tech company Omnicell (NASDAQ:OMCL) jumped 5.9% in the afternoon session after the company reported impressive preliminary second quarter 2025 and full-year profit guidance due to reduced tariffs on imports in China.

Omnicell, Inc. authorizes a Buyback Plan.

2025-05-22
The Board of Directors of Omnicell, Inc. has authorized a buyback plan on May 22, 2025....

Omnicell, Inc. announces an Equity Buyback for $75 million worth of its shares.

2025-05-22
Omnicell, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of shares of its common stock. Th program does not have an expiration date....

Omnicell Updates Q2, 2025 Earnings Guidance, Approves New $75 Million Share Buyback Plan

2025-05-22
Omnicell (OMCL) said Thursday it updated its Q2 and 2025 non-GAAP earnings guidance based on the "te

Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

2025-05-22
FORT WORTH, Texas, May 22, 2025--Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

Omnicell : Webcast 2025 Annual Meeting of Stockholders, May 21, 2025,

2025-05-21
20 May 2025 10:00 AM Atlantic Daylight Time 21 May 2025 8:30 AM Hawaii Standard Time 21 May 2025 10:00 AM Central...